Ishita Drugs & Industries Ltd Financials
Company Logo

Ishita Drugs & Industries Ltd Financial Statement

Ishita Drugs & Industries Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue5.49
Operating Expense5.05
Net Profit0.30
Net Profit Margin5.46
Earning Per Share1.01
EBIDTA0.44
Effective Tax Rate20.45

Ishita Drugs & Industries Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual15.00
Operating Expenses Annual14.00
Operating Profit Annual1.34
Interest Annual0.07
Depreciation0.11
Net Profit Annual0.87
Tax Annual0.29

Ishita Drugs & Industries Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning4.81
Cash Flow from Operations-3.64
Cash Flow from Investing-0.67
Cash Flow from Financing4.33
Cash Flow at the End4.83

Ishita Drugs & Industries Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)8.87
PBIT Margin (%)8.13
PBT Margin (%)-109.00
Net PROFIT Margin (%)5.80
Return On Networth / Equity (%)8.40
Return On Networth /Employed (%)10
Return On Assets (%)7.08
Total Debt / Equity (X)0.19
Asset Turnover Ratio (%)1.22

Ishita Drugs & Industries Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual0.88
Total Current Assets Annual14.98
Non Current Assets Annual1.31
Total Shareholders Funds Annual10.79
Total Assets Annual16.30

Ishita Drugs & Industries Ltd Earning Calls

No Data Availabe

FAQS on Ishita Drugs & Industries Ltd Financials

As of Sep 11, 2025, Ishita Drugs & Industries Ltd has a market capitalization of 23.48 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Ishita Drugs & Industries Ltd is with a debt-to-equity ratio of 0.36.

In FY 2024 , Ishita Drugs & Industries Ltd recorded a total revenue of approximately 15 Cr marking a significant milestone in the company's financial performance.

Ishita Drugs & Industries Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.1% annually, respectively..

Ishita Drugs & Industries Ltd's current PE ratio is 26.99.

Ishita Drugs & Industries Ltd's ROCE averaged 9.1% from the FY ending March 2023 to 2025, with a median of 8.4%. It peaked at 10.9% in March 2024, reflecting strong capital efficiency over the period..

Ishita Drugs & Industries Ltd's latest EBIT is Rs. 1.23 Cr, surpassing the average EBIT of Rs. 1.05 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions